Cabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia Gravis
By Colin Kellaher
Cabaletta Bio has won Food and Drug Administration authorization to launch a Phase 1/2 study of its CABA-201 investigational therapy in patients with the rare autoimmune disease generalized myasthenia gravis.
The Philadelphia clinical-stage biotechnology company on Monday said the green light expands the clinical development of its lead product candidate beyond rheumatology into neurology, adding that it plans to initiate a study across two parallel patient cohorts based on autoantibody status.
Cabaletta--which previously received FDA approvals to study CABA-201 in lupus, myositis and systemic sclerosis--said it is on track to deliver initial clinical data from patients with lupus and/or myositis in the first half of 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 06, 2023 07:40 ET (12:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks